Supplemental
Net payments due to CRISPR Therapeutics AG related to finite-lived intangible assets
Analysis
StatementCash Flow Statement
SectionSupplemental
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2021
Last reportedQ4 2025Feb 13, 2026
How to read this metric
Indicates the scale of strategic investments or partnerships that are structured through non-cash consideration, such as equity or milestone-based obligations.
Detailed definition
Reflects non-cash transactions related to the acquisition of intangible assets, specifically those involving partnership...
Peer comparison
Common in biotech and pharma for R&D collaborations; specific to companies with heavy reliance on external innovation.
Metric ID:
supplemental_noncash_financing_or_investing_activities_c_90de71Historical Data
5 years
| FY'21 | FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $180.00M | $0.00 | $0.00 |
| YoY Change | — | — | — | -100.0% | — |
Range$0.00 – $180.00M
Avg YoY Growth-100.0%
Median YoY Growth-100.0%
Net payments due to CRISPR Therapeutics AG related to finite-lived intangible assets at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's net payments due to crispr therapeutics ag related to finite-lived intangible assets?
- Vertex Pharmaceuticals (VRTX) reported net payments due to crispr therapeutics ag related to finite-lived intangible assets of $0.00 in Q4 2025.
- What does net payments due to crispr therapeutics ag related to finite-lived intangible assets mean?
- Non-cash payments or obligations related to intangible asset acquisitions.